- $692.21m
- $460.10m
Brief: Immix Biopharma To Present Milestones Achieved To Enable Kick-Off Of 2 Imx-110 Clinical Trials At The 2022 Thinkequity Conference On October 26
Brief: Immixbio Approves 4 Additional Clinical Trial Sites For Imx-110 Clinical Trials
Brief: Immix Biopharma Files Preliminary Prospectus Regarding Offering Of 1.7 Mln Shares Of Common Stock
Immix Bio hits 2-month high on cancer treatment results in mice
Brief: Immix Biopharma Announces Share Repurchase Program
Brief: Immixbio Initiates GMP Manufacturing Of Drug for Inflammatory Bowel Disease
U.S. STOCKS ON THE MOVE-Cedar Fair, PG&E Corp, Chevron Corp
Brief: ImmixBio Initiates IMX-110 GMP Manufacturing Scale-Up
Brief: Immixbio Announces Positive Imx-110 Phase 1B/2A Interim Clinical Trial Safety Data
Immix Bio soars on positive data from cancer drug animal study
Brief: ImmixBio IMX-110 Produced 50% Positive Response Rate In First-Line-Therapy-Resistant Cancer, Surpassing The Standard Of Care In Mice Study
U.S. STOCKS ON THE MOVE-Tesla, Container Store, Apple
U.S. STOCKS ON THE MOVE-Tesla, Armstrong Flooring, Immix Biopharma, BlueCity
NASDAQ RESUMED AT 09:52 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:47 AM
NASDAQ RESUMED AT 09:42 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:35 AM
Immix Biopharma jumps on rare-disease tag for pediatric cancer drug
Brief: FDA Approves Immix Biopharma Rare Pediatric Disease Designation For IMX-110